Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast Cancer

Key Inclusion Criteria: * Ability of participant to understand this study, and participant willingness to sign a written informed consent for this trial. * Histologically confirmed stage I , II or III TNBC (triple-negative breast cancer). * No previous definitive ipsilateral breast surgery for the current breast cancer. * No previous chemotherapy, endocrine therapy, or radiation therapy with therapeutic intent for this cancer. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Adequate organ function * Adequate cardiac function * A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies: * Not a woman of childbearing potential (WOCBP) * A WOCBP who agrees to follow contraceptive guidelines. Key Exclusion Criteria: * Current or anticipated use of other investigational agents while participating in this study. * Participant has received chemotherapy, radiotherapy, or surgery for the treatment of breast cancer. * Participant has metastatic disease. * Participant has inflammatory breast cancer. * Participants with concomitant or previous malignancies within the last 5 years are excluded from the study. * Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g. ductal carcinoma in situ (DCIS), carcinoma in situ of the cervix) that have undergone potential curative therapy are not excluded. * Histor…